Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures

被引：40

作者：

Huang, Xuan

Chau, Cindy H. ^{[1
]}

Figg, William D. ^{[1
]}

机构：

[1] NCI, Mol Pharmacol Sect, Med Oncol Branch, NIH, Bethesda, MD 20892 USA

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2012年 / 5卷

基金：

美国国家卫生研究院;

关键词：

CIRCULATING TUMOR-CELLS; PHASE-II TRIAL; ABIRATERONE ACETATE; CLINICAL-TRIALS; END-POINTS; ANTITUMOR-ACTIVITY; PLUS PREDNISONE; POST-DOCETAXEL; DOUBLE-BLIND; SURVIVAL;

D O I：

10.1186/1756-8722-5-35

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Men with metastatic castration-resistant prostate cancer (mCRPC) carry poor prognosis despite the use of docetaxel-based regimens which has modest survival benefit shown by randomized clinical trials. Significant progress in the discovery of novel therapeutic agents has been made in the past few years. While sipuleucel-T, cabazitaxel, and abiraterone gained regulatory approval in 2010 and 2011, several highly promising candidates/regimens have failed in large scale clinical trials. Challenges remain to optimize the design and interpretation of clinical trial results and develop more effective strategies for mCRPC. In this review, we examined the positive and negative clinical trials in mCRPC in the past and discussed the various aspects of clinical trial design including selection of targets and appropriate outcome measures, biomarker development and implementation, and strategies for combination therapy.

引用

页数：8

共 62 条

[1] Novel targeted therapeutics for metastatic castration-resistant prostate cancer [J].

Antonarakis, Emmanuel S. ;

Carducci, Michael A. ;

Eisenberger, Mario A. .

CANCER LETTERS, 2010, 291 (01) :1-13

[2] Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer [J].

Aragon-Ching, Jeanny B. ;

Jain, Lokesh ;

Gulley, James L. ;

Arlen, Philip M. ;

Wright, John J. ;

Steinberg, Seth M. ;

Draper, David ;

Venitz, Juergen ;

Jones, Elizabeth ;

Chen, Clara C. ;

Figg, William D. ;

Dahut, William L. .

BJU INTERNATIONAL, 2009, 103 (12) :1636-1640

[3] Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven [J].

Attard, Gerhardt ;

Reid, Alison H. M. ;

Yap, Timothy A. ;

Raynaud, Florence ;

Dowsett, Mitch ;

Settatree, Sarah ;

Barrett, Mary ;

Parker, Christopher ;

Martins, Vanessa ;

Folkerd, Elizabeth ;

Clark, Jeremy ;

Cooper, Colin S. ;

Kaye, Stan B. ;

Dearnaley, David ;

Lee, Gloria ;

de Bono, Johann S. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) :4563-4571

[4] Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer [J].

Attard, Gerhardt ;

Reid, Alison H. M. ;

A'Hern, Roger ;

Parker, Christopher ;

Oommen, Nikhil Babu ;

Folkerd, Elizabeth ;

Messiou, Christina ;

Molife, L. Rhoda ;

Maier, Gal ;

Thompson, Emilda ;

Olmos, David ;

Sinha, Rajesh ;

Lee, Gloria ;

Dowsett, Mitch ;

Kaye, Stan B. ;

Dearnaley, David ;

Kheoh, Thian ;

Molina, Arturo ;

de Bono, Johann S. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) :3742-3748

[5] Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer [J].

Attard, Gerhardt ;

Swermenhuis, Joost F. ;

Olmos, David ;

Reid, Alison H. M. ;

Vickers, Elaine ;

A'Hern, Roger ;

Levink, Rianne ;

Coumans, Frank ;

Moreira, Joana ;

Riisnaes, Ruth ;

Oommen, Nikhil Babu ;

Hawche, George ;

Jameson, Charles ;

Thompson, Emilda ;

Sipkema, Ronald ;

Carden, Craig P. ;

Parker, Christopher ;

Dearnaley, David ;

Kaye, Stan B. ;

Cooper, Colin S. ;

Molina, Arturo ;

Cox, Michael E. ;

Terstappen, Leon W. M. M. ;

de Bono, Johann S. .

CANCER RESEARCH, 2009, 69 (07) :2912-2918

[6] Modes of resistance to anti-angiogenic therapy [J].

Bergers, Gabriele ;

Hanahan, Douglas .

NATURE REVIEWS CANCER, 2008, 8 (08) :592-603

[7] Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group [J].

Bubley, GJ ;

Carducci, M ;

Dahut, W ;

Dawson, N ;

Daliani, D ;

Eisenberger, M ;

Figg, WD ;

Freidlin, B ;

Halabi, S ;

Hudes, G ;

Hussain, M ;

Kaplan, R ;

Myers, C ;

Oh, W ;

Petrylak, DP ;

Reed, E ;

Roth, B ;

Sartor, O ;

Scher, H ;

Simons, J ;

Sinibaldi, V ;

Small, EJ ;

Smith, MR ;

Trump, DL ;

Vollmer, R ;

Wilding, G .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3461-3467

[8] Use of Meta-Analysis for the Validation of Surrogate Endpoints and Biomarkers in Cancer Trials [J].

Buyse, Marc .

CANCER JOURNAL, 2009, 15 (05) :421-425

[9] Targeting bone metastasis in prostate cancer with endothelin receptor antagonists [J].

Carducci, Michael A. ;

Jimeno, Antonio .

CLINICAL CANCER RESEARCH, 2006, 12 (20) :6296S-6300S

[10] A phase II clinical trial of sorafenib in androgen-independent prostate cancer [J].

Dahut, William L. ;

Scripture, Charity ;

Posadas, Edwin ;

Jain, Lokesh ;

Gulley, James L. ;

Arlen, Philip M. ;

Wright, John J. ;

Yu, Yunkai ;

Cao, Liang ;

Steinberg, Seth M. ;

Aragon-Ching, Jeanny B. ;

Venitz, Juergen ;

Jones, Elizabeth ;

Chen, Clara C. ;

Figg, William D. .

CLINICAL CANCER RESEARCH, 2008, 14 (01) :209-214

← 1 2 3 4 5 6 7 →